Project Grant R01CA302481
Award Date 6/1/26
Completion Date 5/30/31
Dollars Obligated $659K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $707,798 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-refractory form shortly after...
- Federal Grant Award Summary The National Cancer Institute awarded a $176,040 Project Grant to Massachusetts General Hospital under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025 through June 30, 2027. The award funds research to develop engineered CAR-T (Chimeric Antigen Receptor T) cell therapies capable of overcoming the cancer cell glycocalyx barrier, a protective layer that impedes immune cell recognition and destruction of solid tumors. The research addresses a...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning March 13, 2026, with completion targeted for February 28, 2029. This award supports the development and application of high-throughput tools designed to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events that drive oncogenic mechanisms...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital $628,373 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 1, 2025, for a five-year project period extending through June 30, 2030. This Project Grant supports fundamental and translational research focused on understanding the immunobiology of conventional dendritic cells (CDC1) and their...
- Federal Grant Award Summary Massachusetts General Hospital received a $684,107 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 18, 2025, with a completion date of July 31, 2030. The grant supports research into the integration of circulating tumor cell (CTC) and nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- Federal Grant Award Summary The National Cancer Institute awarded $2.82 million to the Regents of the University of Michigan under the Cancer Treatment Research program (CFDA 93.395) on August 6, 2025, with completion targeted for July 31, 2029. This Project Grant supports the development of new methods to measure metabolic pathway activity in glioblastomas (GBMs), deadly brain cancers that rewire their metabolism to enable growth, invasion, and treatment resistance. The research deliverables...
- Federal Project Grant Award Summary Georgetown University has received a $656,469 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026, through May 31, 2031. This five-year research award supports fundamental laboratory research investigating the regulation of de novo nucleotide synthesis and glioblastoma (GBM) response to radiochemotherapy. The project focuses on elucidating the molecular mechanisms by which the...